Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labcorp HoldingsLTS:0JSY +0.92%75 Days Sales Outstanding is 56.63 as of Jun. 2026, which is 7% above its 10-year median of 52.74. GuruFocus rates LTS:0JSY with a GF Score™ of 75/100 and a GF Value™ of $277.17 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Labcorp Holdings ranks better than 62.38% on this metric.
The historical rank and industry rank for Labcorp Holdings's Days Sales Outstanding or its related term are showing as below:
LTS:0JSY'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.57 Med: 52.74 Max: 65.87
Current: 55.79
During the past 13 years, Labcorp Holdings's highest Days Sales Outstanding was 65.87. The lowest was 47.57. And the median was 52.74.
LTS:0JSY's Days Sales Outstanding is ranked better than 62.38% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.855
vs LTS:0JSY: 55.79
Labcorp Holdings's Days Sales Outstanding
increased
from Jun. 2025 (54.89) to Jun. 2026 (56.63).
Labcorp Holdings (LTS:0JSY) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Labcorp Holdings Days Sales Outstanding Related Terms
Labcorp Holdings Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Labcorp Holdings's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JSY vs DGX, MTD, GH: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Labcorp Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's Days Sales Outstanding falls into.
Labcorp Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (LTS:0JSY) has a Days Sales Outstanding of 56.63 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Labcorp Holdings and its competitors. This is near median its historical median of 52.74. Over the past decade, Labcorp Holdings' Days Sales Outstanding has ranged from 47.57 to 65.87. According to the industry distribution chart, Labcorp Holdings ranks #76 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 37.6%.
Is Labcorp Holdings' Days Sales Outstanding too high?
Labcorp Holdings' current Days Sales Outstanding of 56.63 is near median its 10-year median of 52.74. Over the past 10 years, this metric has ranged from a low of 47.57 to a high of 65.87. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.86. Labcorp Holdings' value of 56.63 is 16.5% below this industry median. Based on the distribution chart, Labcorp Holdings ranks #76 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Labcorp Holdings has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' Days Sales Outstanding compare to DGX and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #76 out of 202 companies for Days Sales Outstanding. This puts Labcorp Holdings in the upper half of its industry. The industry median Days Sales Outstanding is 67.86. Labcorp Holdings' value of 56.63 is 16.5% below this benchmark. Historically, Labcorp Holdings' own Days Sales Outstanding has ranged from 47.57 to 65.87 over the past decade. While the company's 10-year median is 52.74 vs. the industry median of 67.86, Labcorp Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.86, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current Days Sales Outstanding of 56.63 is 16.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current Days Sales Outstanding is 56.63, which is near median its own 10-year median of 52.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LTS:0JSY) is currently considered Modestly Overvalued. The stock's GF Value™ is $277.17, compared to a current price of $337.45 — trading 21.7% above its estimated fair value. The current Days Sales Outstanding is 56.63, which is near median its 10-year median of 52.74 and 16.5% below the Medical Diagnostics & Research industry median of 67.86. Labcorp Holdings' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Labcorp Holdings (LTS:0JSY), the current Days Sales Outstanding is 56.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LTS:0JSY) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $337.45 is trading 21.7% above its estimated GF Value™ of $277.17.
GuruFocus considers Labcorp Holdings to be Modestly Overvalued.
Key valuation signals for LTS:0JSY:
Days Sales Outstanding: 56.63 (near median its 10-year median of 52.74)
GF Value™: $277.17 vs. price of $337.45 (21.7% above fair value)
Industry Position: 16.5% below the Medical Diagnostics & Research median (#76 of 202)
No single metric tells the full story. See the LTS:0JSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
75GF Score
Get the complete analysis for LTS:0JSY
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JSY has been successfully added to your 
